GLP-1 Use Linked to Shifts in Consumer Snack Habits
As weight-loss drug use rises, researchers are monitoring how appetite changes influence the types of foods Americans buy.
Updated on Sept. 21, 2026 in Weight Loss
Live Poll
Do you trust the long-term future of major snack food brands given changing health trends?
Brand Finance identified Lay's as the food brand most vulnerable to reduced snacking, as GLP-1 usage for weight loss among U.S. adults reached 11%. This shift coincides with research showing that individuals taking these medications consume approximately 700 fewer calories per day.
Why it matters
Consumers on GLP-1 drugs frequently reduce their intake of calorie-dense and heavily processed snack foods, forcing a reevaluation of food production priorities. This trend may eventually result in more food options aligned with lower calorie requirements as manufacturers adapt to smaller appetites.
A Brand Finance analysis found that 45% of the Lay's brand value is tied to categories at risk from reduced snacking. Furthermore, Cornell University research observed a 6% drop in grocery spending within households containing at least one user of weight-loss medication.
The players
Lay's
A snack food brand identified as highly exposed to reduced consumer demand resulting from GLP-1 drug usage.
Cornell University
An academic institution that conducted research on the impact of weight-loss drugs on household grocery spending.
Brand Finance
A brand valuation consultancy that analyzed which food products are most vulnerable to changes in eating patterns.
The details
GLP-1 medications work by curbing appetite, which leads users to decrease consumption of refined grains, sugar-sweetened beverages, processed foods, and beef. To preserve profit margins in this environment, manufacturers may prioritize product innovation or the acquisition of different brands that better suit the needs of users with smaller appetites.
Timeline
GLP-1 use among U.S. adults was 3% in 2024.
A report on GLP-1 consumption habits was published in 2025.
Brand Finance published its analysis of food brand exposure in September 2026.
Health Landscape
This analysis builds upon the established trend of shifting consumer dietary habits following the rise of weight-loss pharmacotherapy. It updates figures previously established by the 2025 FAIR report on GLP-1 consumption habits.
If you are using GLP-1 medications, you may notice significant changes in your appetite and a reduced interest in certain processed snacks. It is worth discussing your changing nutritional needs and dietary goals with your doctor to ensure you maintain adequate intake of essential nutrients.
The takeaway
The rise of weight-loss drugs is fundamentally changing consumer demand for calorie-dense foods. Readers should focus on prioritizing nutrient-dense whole foods and consult a physician if they have concerns about unintended weight loss or significant shifts in their overall caloric intake.
Further reading
For more on the intersection of nutrition and weight management, visit our Weight Loss section.
Live Poll
Do you trust the long-term future of major snack food brands given changing health trends?
